Glaucoma: Current and developing concepts for inflammation, pathogenesis and treatment

European Journal of Inflammation

Volumn 4, Issue 3, 2006, Pages 129-137

  Kumarasamy, Normandan A ^b,c   Lam, F S ^b   Wang, A L ^b   Theoharides, T C ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS UNIVERSITY   (United States)

^c HHMI   (United States)

Author keywords

Autoimmunity; Erythropoietin; Glaucoma; Glutamate neurotoxicity; Neuroprotection

Indexed keywords

ACETAZOLAMIDE; ALPHA 2 ADRENERGIC RECEPTOR; AUTOANTIGEN; BETA 1 ADRENERGIC RECEPTOR; BETAXOLOL; BIMATOPROST; CALCIUM CHANNEL BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; CASPASE 3 INHIBITOR; CYTOKINE; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; ERYTHROPOIETIN; GINKGO BILOBA EXTRACT; GLUTAMATE RECEPTOR; GLUTAMIC ACID DERIVATIVE; HEAT SHOCK PROTEIN 72; INDUCIBLE NITRIC OXIDE SYNTHASE; IONOTROPIC RECEPTOR; MUSCARINIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID; NEUROTROPHIC FACTOR; NIPRADILOL; NITRIC OXIDE; PROSTAGLANDIN F2 ALPHA DERIVATIVE; PROTEIN P75; PROTEIN TYROSINE KINASE A; STAT3 PROTEIN; TIMOLOL; VACCINE;

APOPTOSIS; AUTOIMMUNE DISEASE; BLINDNESS; BLURRED VISION; CALCIUM CELL LEVEL; CELL DEATH; CONCEPT FORMATION; CONTROLLED STUDY; CONVENIENCE SAMPLE; COST; DEGENERATIVE DISEASE; DESTRUCTION; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG MECHANISM; EYE; GLAUCOMA; HUMAN; HYPOTONY MACULOPATHY; INFLAMMATION; INTRAOCULAR PRESSURE; LOW LEVEL LASER THERAPY; NEUROPROTECTION; NEUROTOXICITY; OPEN ANGLE GLAUCOMA; OPTIC NERVE DISEASE; PATHOGENESIS; RETINA GANGLION CELL; REVIEW; RISK FACTOR; SAFETY; SECOND MESSENGER; SYSTEMIC DISEASE; T LYMPHOCYTE ACTIVATION; THERAPY; TRABECULECTOMY;

EID: 33751237048     PISSN: 1721727X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1721727X0600400301     Document Type: Review

References (40)

1. Weinreb R.N. and P.T. Khaw. 2004. Primary open-angle glaucoma. Lancet 363:1711.
2. Margalit E. and S.R. Sadda. 2003. Retinal and optic nerve diseases. Artif. Organs 27:963.
3. Spry P.G., J.M. Sparrow, J.P. Diamond and H.S. Harris. 2005. Risk factors for progressive visual field loss in primary open angle glaucoma. Eye 19:643.
4. Friedman D.S., M.R. Wilson, J.M. Liebmann, R.D. Fechtner and R.N. Weinreb. 2004. An evidence-based assessment of risk factors for the progression of ocular hypertension and glaucoma. Am. J. Ophthalmol. 138:S19.
5. Alward W.L. 1998. Medical management of glaucoma. N. Engl. J. Med. 339:1298.
6. Cohen C.S. and R.R. Allingham. 2004. The dawn of genetic testing for glaucoma. Curr. Opin. Ophthalmol. 15:75.
7. Ullian E.M., W.B. Barkis, S. Chen, J.S. Diamond and B.A. Barres. 2004. Invulnerability of retinal ganglion cells to NMDA excitotoxicity. Mol. & Cell. Neurosci. 26:544.
8. Dyka F.M., C.A. May and R. Enz. 2004. Metabotropic glutamate receptors are differentially regulated under elevated intraocular pressure. J. Neurochem. 90:190.
9. Tehrani A., T.H. Wheeler-Schilling and E. Guenther. 2000. Coexpression patterns of mGLuR mRNAs in rat retinal ganglion cells: a single-cell RT-PCR study. Invest. Ophthalmol. Vis. Sci. 41:314.
10. Whitmore A.V., R.T. Libby and S.W. John. 2005. Glaucoma: thinking in new ways-a role for autonomous axonal self-destruction and other compartmentalised processes? Progress in Retinal & Eye Res. 24:639.
11. Liu B. and A.H. Neufeld. 2003. Activation of epidermal growth factor receptor signals induction of nitric oxide synthase-2 in human optic nerve head astrocytes in glaucomatous optic neuropathy. Neurobiol. Dis. 13:109.
12. Neufeld A.H. 2004. Pharmacologic neuroprotection with an inhibitor of nitric oxide synthase for the treatment of glaucoma. Brain Res. Bull. 62:455.
13. Brubaker R.F. 2003. Introduction: three targets for glaucoma management. Surv. Ophthalmol. 48:S1.
14. Rudzinski M., T.P. Wong and H.U. Saragovi. 2004. Changes in retinal expression of neurotrophins and neurotrophin receptors induced by ocular hypertension. J. Neurobiol. 58:341.
15. Lambert W.S., A.F. Clark and R.J. Wordinger. 2004. Effect of exogenous neurotrophins on Trk receptor phosphorylation, cell proliferation, and neurotrophin secretion by cells isolated from the human lamina cribrosa. Mol. Vision 10:289.
16. Yang J., R.V. Patil, H. Yu, M. Gordon and M.B. Wax. 2001. T cell subsets and sIL-2R/IL-2 levels in patients with glaucoma. Am. J. Ophthalmol. 131:421.
17. Tezel G., J. Yang and M.B. Wax. 2004. Heat shock proteins, immunity and glaucoma. Brain Res. Bull. 62:473.
18. Tezel G. and M.B. Wax. 2004. The immune system and glaucoma. Curr. Opin. Ophthalmol. 15:80.
19. Wax M.B. 2000. Is there a role for the immune system in glaucomatous optic neuropathy?. Curr. Opin. Ophthalmol. 11:145.
20. Bakalash S., J. Kipnis, E. Yoles and M. Schwartz. 2002. Resistance of retinal ganglion cells to an increase in intraocular pressure is immune-dependent. Invest. Ophthalmol. Vis. Sci. 43:2648.
21. Bakalash S., A. Kessler, T. Mizrahi, R. Nussenblatt and M. Schwartz. 2003. Antigenic specificity of immunoprotective therapeutic vaccination for glaucoma. Invest. Ophthalmol. Vis. Sci. 44:3374.
22. Fechtner R.D. and T. Realini. 2004. Fixed combinations of topical glaucoma medications. Curr. Opin. Ophthalmol. 15:132.
23. Woodward D.F. and D.W. Gil. 2004. The inflow and outflow of anti-glaucoma drugs. Trends Pharmacol. Sci. 25:238.
24. Schwartz K. and D. Budenz. 2004. Current management of glaucoma. Curr. Opin. Ophthalmol. 15:119.
25. Khaw P.T., P. Shah and A.R. Elkington. 2004. Glaucoma-2: treatment. BMJ 328:156.
26. Lipton S.A. 2003. Possible role for memantine in protecting retinal ganglion cells from glaucomatous damage. Surv. Ophthalmol. 48:S38.
27. Tomita H., T. Nakazawa, E. Sugano, T. Abe and M. Tamai. 2002. Nipradilol inhibits apoptosis by preventing the activation of caspase-3 via S-nitrosylation and the cGMP-dependent pathway. Eur. J. Pharmacol. 452:263.
28. Bartlett H. and F. Eperjesi. 2004. An ideal ocular nutritional supplement? Ophthalmic & Physiological Optics 24:339.
29. Hirooka K., M. Tokuda, O. Miyamoto, T. Itano, T. Baba and F. Shiraga. 2004. The Ginkgo biloba extract (EGb 761) provides a neuroprotective effect on retinal ganglion cells in a rat model of chronic glaucoma. Curr. Eye Res. 28:153.
30. Quaranta L., S. Bettelli, M.G. Uva, F. Semeraro, R. Turano and E. Gandolfo. 2003. Effect of Ginkgo biloba extract on preexisting visual field damage in normal tension glaucoma. Ophthalmology 110:359.
31. Sucher N.J., S.A. Lipton and E.B. Dreyer. 1997. Molecular basis of glutamate toxicity in retinal ganglion cells. Vision Res. 37:3483.
32. Osborne N.N., J.P. Wood, A. Cupido, J. Melena and G. Chidlow. 2002. Topical flunarizine reduces IOP and protects the retina against ischemia-excitotoxicity. Invest. Ophthalmol. Vis. Sci. 43:1456.
33. Thanos S. and R. Naskar. 2004. Correlation between retinal ganglion cell death and chronically developing inherited glaucoma in a new rat mutant Exp. Eye Res. 79:119.
34. Adamus G., B. Sugden, S. Shiraga, A.M. Timmen and W.W. Hauswirth. 2003. Anti-apoptotic effects of CNTF gene transfer on photoreceptor degeneration in experimental antibody-induced retinopathy. J.Autoimmun. 21:121.
35. Boyd Z.S., A. Kriatchko, J. Yang, N. Agarwal, M.B. Wax and R.V. Patil. 2003. Interleukin-10 receptor signaling through STAT-3 regulates the apoptosis of retinal ganglion cells in response to stress. Invest. Ophthalmol. Vis. Sci. 44:5206.
36. McKinnon S.J., D.M. Lehman, N.G. Tahzib, N.L. Ransom, H.A. Reitsamer, P. Liston, et al. 2002. Baculoviral IAP repeat-containing-4 protects optic nerve axons in a rat glaucoma model. Mol. Therapy: 5:780.
37. Baptiste D.C., A.T. Hartwick, C.A. Jollimore, W.H. Baldridge, G.M. Seigel and M.E. Kelly. 2004. An investigation of the neuroprotective effects of tetracycline derivatives in experimental models of retinal cell death. Mol. Pharmacol. 66:1113.
38. Ishii Y., J.M. Kwong and J. Caprioli. 2003. Retinal ganglion cell protection with geranylgeranylacetone, a heat shock protein inducer, in a rat glaucoma model. Invest. Ophthalmol. Vis. Sci. 44:1982.
39. Weishaupt J.H., G. Rohde, E. Polking, A.L. Siren, H. Ehrenreich and M. Bahr. 2004. Effect of erythropoietin axotomy-induced apoptosis in rat retinal ganglion cells. Invest. Ophthalmol. Vis. Sci. 45:1514.
40. Chong Z.Z., S.H. Lin, J.Q. Kang and K. Maiese. 2003. Erythropoietin prevents early and late neuronal demise through modulation of Akt1 and induction of caspase 1, 3 and 8. J. Neurosci. Res. 71:659.